Luye Pharma Group Ltd. (HKG:2186)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 11.42B |
| Revenue (ttm) | 6.76B |
| Net Income (ttm) | 434.95M |
| Shares Out | 3.99B |
| EPS (ttm) | 0.12 |
| PE Ratio | 24.74 |
| Forward PE | 14.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,240,900 |
| Average Volume | 15,602,455 |
| Open | 2.840 |
| Previous Close | 2.860 |
| Day's Range | 2.830 - 2.890 |
| 52-Week Range | 1.670 - 4.490 |
| Beta | 1.09 |
| RSI | 42.61 |
| Earnings Date | Mar 27, 2026 |
About Luye Pharma Group
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg... [Read more]
Financial Performance
In 2024, Luye Pharma Group's revenue was 6.06 billion, a decrease of -1.33% compared to the previous year's 6.14 billion. Earnings were 471.89 million, a decrease of -11.40%.
Financial numbers in CNY Financial StatementsNews
Luye Pharma Grants Nhwa Rights To Commercialize Three LAI Antipsychotics In Chinese Mainland
(RTTNews) - The board of Luye Pharma Group Ltd. (2186.HK) announced that certain subsidiaries of the Group have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., a subsid...
RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019
RRJ Capital, founded by former Goldman Sachs Group Inc. banker Richard Ong, will fully subscribe to the $150 million convertible bonds issued by Luye Pharma Group Ltd., marking its first investment in...